Canine Dilated Cardiomyopathy Drugs Market

Canine dilated cardiomyopathy drugs are used to treat heart muscle diseases which causes the heart to weaken and enlarge. This results in weaken contraction and poor pumping ability of the heart. The canine dilated cardiomyopathy is prevalent in certain breeds of dog and observed to be rare in crossbreeds dogs. Canine dilated cardiomyopathy drugs are directed at enhancing systolic (pump) function of the heart, dilating the peripheral blood vessels to lower ventricular workload, controlling heart rate and cardiac arrhythmias. Canine dilated cardiomyopathy drugs treatment goals are achieved by the administration of cardiac medication which may be delivered through injections in an emergency situation or orally in stable animals.

Canine Dilated Cardiomyopathy Drugs Market: Drivers and Restraints

The major factors for the growth of canine dilated cardiomyopathy drugs market are the potential growth of the pet industry. Dogs are estimated to account for the largest share in the pet industry due to rising health benefits for pet animals. Additionally, increasing prevalence of cardiac diseases, technological advancement in the diagnostic treatments, and more life expectancy of animals are the other factors contributing to the growth of canine dilated cardiomyopathy drugs market. However, the high cost and side effects associated with products and treatment are expected to restrain the growth of canine dilated cardiomyopathy additionally growth. Moreover, lack of veterinary infrastructure, poor transportation link in some of the region are the other factors expected to hamper the growth of canine dilated cardiomyopathy drugs market.